The Board of Directors of BONESUPPORT HOLDING AB (“BONESUPPORT”) has, pursuant to the authorization granted by the 2026 annual general meeting, resolved to initiate a share buy-back program of up to SEK 100 million for the purpose of adapting BONESUPPORT’s capital structure to the company’s capital needs and thereby contribute to increased shareholder value. The program commences at the earliest on September 1, 2026 and will end at the latest on October 30, 2026.

The acquisition of ordinary shares will be carried out in accordance with the Market Abuse Regulation (EU) 596/2014 ("MAR") and the European Commission's Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). The acquisition of shares will be managed by DNB Carnegie Investment Bank AB that will make its own trading decisions regarding the timing of the acquisitions independently of BONESUPPORT.

The Board of Directors intends to propose that the acquired shares be cancelled through a reduction of BONESUPPORT’s share capital at the next Annual General Meeting.

The following terms and conditions apply to the acquisitions of shares:

• Acquisition of shares shall be made on Nasdaq Stockholm in accordance with Nasdaq Stockholm’s Main Market Rulebook for Issuers of Shares, MAR and the Safe Harbour Regulation.
• Acquisitions of shares may be made on one or several occasions and shall commence no earlier than September 1, 2026 and shall end no later than October 30, 2026.
  
• The maximum total repurchase amount is SEK 100 million. In accordance with the Swedish Companies Act and the authorization granted by the 2026 annual general meeting, shares may be acquired only to the extent that BONESUPPORT’s total holding of own shares does not exceed 10 percent of the total number of shares in the company.
• Acquisitions shall be made in compliance with the volume and price restrictions set out in Nasdaq Stockholm’s Main Market Rulebook for Issuers of Shares and in the Safe Harbour Regulation, and shall not be made at a price lower than the lowest price at which an independent purchase may take place.
  
• Payment for acquired shares shall be made in cash.

As per September 1, 2026, the total number of shares in BONESUPPORT is 66,764,350, of which 65,859,195 are ordinary shares and 905,155 are Series C shares. BONESUPPORT’s holdings of treasury shares amount to 373,320 ordinary shares and 905,155 Series C shares as per the same date.

For more information contact:

BONESUPPORT Holding AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

BONESUPPORT initiates share buy-back program of up to SEK 100 million